Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

NEW YORK, NY / ACCESS Newswire / February 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) ...

Vertex Pharmaceuticals expects another year of rapid growth in 2025, after achieving this in the fourth quarter and ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc ... providers who participated in the clinical trials and made this approval possible.

Good day and welcome to the Vertex Pharmaceuticals fourth quarter of 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over ...

Healthcare isn't the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months, healthcare ...

Good day, and welcome to the Vertex Pharmaceuticals Fourth Quarter ... who participated in the clinical trials and made this approval possible. With these two recent approvals for ALYFTREK and ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

A newly approved pain medication, suzetrigine, is the first nonopioid analgesic in 25 years to receive clearance from the U.S ...

Vertex Pharmaceuticals dominates the market ... Sionna has mapped out a clinical trial strategy that could validate its different approach to the chronic respiratory disease.